ドロップダウンアイコン
ドロップダウンアイコン
ドロップダウンアイコン
ドロップダウンアイコン
JP
/
EN
メニューアイコン
Award
Craif Wins the Top Prize at GRIC PITCH, the Global Pitch Stage of Japan's GRIC2025 Conference
2025.11.19

COO Mika Mizunuma pitched Craif's urine based cancer risk test as one of 18 startups on stage, in front of more than 120 judges from Japan and overseas. Craif also took the UPRISING DIGITAL Theme AWARD and a SPONSOR PRIZE.

TOKYO, November 19, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, won the top prize at GRIC PITCH, the global pitch stage of the GRIC2025 growth industry conference, on Thursday, November 13, 2025. COO Mika Mizunuma delivered the pitch.

Craif's pitch was titled Transform Cancer Care through Bio AI-Powered Urine Test.

The awards

  • GRAND AWARD, the top prize
  • Theme AWARD for UPRISING DIGITAL
  • SPONSOR PRIZE from AGS Consulting Co., Ltd. and Zoom Communications Inc.

Comment from Craif COO Mika Mizunuma

"We are sharpening our bio x AI technology to put an end to the fight against cancer, and we are now moving toward entry into the US market. We will keep working to change the world with technology from Japan. The name Craif combines Crane with Life. The crane is a symbol of Japan, and the idea is of that crane taking flight to the rest of the world and changing people's lives. We intend to live up to the name."

The awards came from a startup pitch competition and reflect how judges assessed Craif's business and its global potential. They are not a clinical or analytical result.

About GRIC (GROWTH INDUSTRY CONFERENCE)

GRIC (GROWTH INDUSTRY CONFERENCE) is a conference whose stated purpose is to take Japan's startup ecosystem global, and one of the largest of its kind in Japan. GRIC2025, the sixth edition, ran from Tuesday, November 11 to Thursday, November 13, 2025, both online and in person, and drew more than 12,000 registrations.

About GRIC PITCH

GRIC PITCH is a pitch contest that offers startups a chance to compete for global attention. It was divided into three themes, CLIMATE TECH & RESILIENCE, FRONTIER TECH, and UPRISING DIGITAL. Eighteen startups seen as having global potential took the stage, and they were judged by more than 120 judges from Japan and overseas.

About miSignal Scan

miSignal Scan extracts microRNA from urine and analyzes it with AI to assess the risk of 10 cancer types, including pancreatic cancer, by cancer type and from Stage 1.

Ovarian and breast cancer risk is assessed for women only. Prostate cancer risk is assessed for men only.

About Craif

Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.

Important notice

miSignal Scan is not a medical device. It determines risk by applying statistical calculation to the information it analyzes. It is not a substitute for a medical diagnosis of whether a person has cancer, and a result indicating low risk does not mean that cancer is absent or that the person will not develop cancer in the future.

Media contact

press_us@craif.com